Advanced search
2 files | 829.72 KB Add to list

Eculizumab improves fatigue in refractory generalized myasthenia gravis

(2019) QUALITY OF LIFE RESEARCH. 28(8). p.2247-2254
Author
Organization
Abstract
Purpose: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate correlations between improvements in Neuro-QOL Fatigue and other clinical endpoints. Methods: Neuro-QOL Fatigue, MG Activities of Daily Living (MG-ADL), Quantitative MG (QMG), and the 15-item MG Quality of Life (MG-QOL15) scales were administered during the phase 3, randomized, placebo-controlled REGAIN study (eculizumab, n=62; placebo, n=63) and subsequent open-label extension (OLE). Data were analyzed using repeated-measures models. Correlations between changes in Neuro-QOL Fatigue and in MG-ADL, QMG, and MG-QOL15 scores were determined at REGAIN week 26. Results: At REGAIN week 26, eculizumab-treated patients showed significantly greater improvements in Neuro-QOL Fatigue scores than placebo-treated patients (consistent with improvements in MG-ADL, QMG, and MG-QOL15 scores previously reported in REGAIN). Improvements with eculizumab were sustained through OLE week 52. Correlations between Neuro-QOL Fatigue and MG-QOL15, MG-ADL, and QMG scores were strong for eculizumab-treated patients at REGAIN week 26, and strong, moderate, and weak, respectively, for placebo-treated patients. Conclusions: Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures.
Keywords
Eculizumab, Myasthenia gravis, Fatigue, Neuro-QOL Fatigue, Quality of life, Terminal complement inhibition, Complement, QUALITY-OF-LIFE, COMPLEMENT

Downloads

  • Andersen2019 Article EculizumabImprovesFatigueInRef.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 794.93 KB
  • 11136 2019 2148 MOESM1 ESM.docx
    • supplementary material
    • |
    • open access
    • |
    • Word
    • |
    • 34.79 KB

Citation

Please use this url to cite or link to this publication:

MLA
Andersen, Henning et al. “Eculizumab Improves Fatigue in Refractory Generalized Myasthenia Gravis.” QUALITY OF LIFE RESEARCH 28.8 (2019): 2247–2254. Print.
APA
Andersen, Henning, Mantegazza, R., Wang, J. J., O’Brien, F., Patra, K., Howard, J. F., Jr, REGAIN Study Group, the, et al. (2019). Eculizumab improves fatigue in refractory generalized myasthenia gravis. QUALITY OF LIFE RESEARCH, 28(8), 2247–2254.
Chicago author-date
Andersen, Henning, Renato Mantegazza, Jing Jing Wang, Fanny O’Brien, Kaushik Patra, James F Howard Jr, the REGAIN Study Group, and Jan De Bleecker. 2019. “Eculizumab Improves Fatigue in Refractory Generalized Myasthenia Gravis.” Quality of Life Research 28 (8): 2247–2254.
Chicago author-date (all authors)
Andersen, Henning, Renato Mantegazza, Jing Jing Wang, Fanny O’Brien, Kaushik Patra, James F Howard Jr, the REGAIN Study Group, and Jan De Bleecker. 2019. “Eculizumab Improves Fatigue in Refractory Generalized Myasthenia Gravis.” Quality of Life Research 28 (8): 2247–2254.
Vancouver
1.
Andersen H, Mantegazza R, Wang JJ, O’Brien F, Patra K, Howard JF Jr, et al. Eculizumab improves fatigue in refractory generalized myasthenia gravis. QUALITY OF LIFE RESEARCH. 2019;28(8):2247–54.
IEEE
[1]
H. Andersen et al., “Eculizumab improves fatigue in refractory generalized myasthenia gravis,” QUALITY OF LIFE RESEARCH, vol. 28, no. 8, pp. 2247–2254, 2019.
@article{8618349,
  abstract     = {Purpose: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate correlations between improvements in Neuro-QOL Fatigue and other clinical endpoints. 
Methods: Neuro-QOL Fatigue, MG Activities of Daily Living (MG-ADL), Quantitative MG (QMG), and the 15-item MG Quality of Life (MG-QOL15) scales were administered during the phase 3, randomized, placebo-controlled REGAIN study (eculizumab, n=62; placebo, n=63) and subsequent open-label extension (OLE). Data were analyzed using repeated-measures models. Correlations between changes in Neuro-QOL Fatigue and in MG-ADL, QMG, and MG-QOL15 scores were determined at REGAIN week 26. 
Results: At REGAIN week 26, eculizumab-treated patients showed significantly greater improvements in Neuro-QOL Fatigue scores than placebo-treated patients (consistent with improvements in MG-ADL, QMG, and MG-QOL15 scores previously reported in REGAIN). Improvements with eculizumab were sustained through OLE week 52. Correlations between Neuro-QOL Fatigue and MG-QOL15, MG-ADL, and QMG scores were strong for eculizumab-treated patients at REGAIN week 26, and strong, moderate, and weak, respectively, for placebo-treated patients. 
Conclusions: Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures.},
  author       = {Andersen, Henning and Mantegazza, Renato and Wang, Jing Jing and O'Brien, Fanny and Patra, Kaushik and Howard, James F, Jr and REGAIN Study Group, the and De Bleecker, Jan},
  issn         = {0962-9343},
  journal      = {QUALITY OF LIFE RESEARCH},
  keywords     = {Eculizumab,Myasthenia gravis,Fatigue,Neuro-QOL Fatigue,Quality of life,Terminal complement inhibition,Complement,QUALITY-OF-LIFE,COMPLEMENT},
  language     = {eng},
  number       = {8},
  pages        = {2247--2254},
  title        = {Eculizumab improves fatigue in refractory generalized myasthenia gravis},
  url          = {http://dx.doi.org/10.1007/s11136-019-02148-2},
  volume       = {28},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: